References
- Vardiman JW, Arber D, Brunning R, . Therapy-related myeloid neoplasms. In: Swerdlow S, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press; 2008. pp. 127–129.
- Bacher U, Haferlach C, Alpermann T, . Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2013;54;636–639.
- Singh ZN, Huo D, Anastasi J, . Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007;127:197–205.
- Greenberg PL, Tuechler H, Schanz J, . Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012 Jun 27. [Epub ahead of print]
- Kantarjian HM, Keating MJ, Walters RS, . Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986;4:1748–1757.
- Mauritzson N, Albin M, Rylander L, . Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 2002;16:2366–2378.
- Schoch C, Kern W, Schnittger S, . Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120–125.
- Gustafson SA, Lin P, Chen SS, . Therapy-related acute myeloid leukemia with t(8;21)(q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 2009;131:647–655.
- Larson RA, Le Beau MM.Prognosis and therapy when acute promyelocytic leukemia and other “good risk” acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis 2011;3:e2011032.
- Feldman EJ.Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?Best Pract Res Clin Haematol 2011;24:523–526.
- Armand P, Kim HT, DeAngelo DJ, . Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007;13:655–664.